WeVote
Log In

Bill

Bill

SB 1804

SB 1804 - This act provides that certain professional licensing boards shall not grant any regulatory mitigation or waive or modify any rules related to dispensing, prescribing, administering, or otherwise distributing, including renewing, medications or controlled substances to a person or business developing, creating, or generating artificial intelligence for such prescription activities. KATIE O'BRIEN

2026 Regular Session

Missouri bill bans licensing boards from granting regulatory waivers to AI developers working on prescription drug dispensing and administration systems.

Second Read and Referred S Emerging Issues and Professional Registration Committee
0
WeVote Research Nonpartisan
Bill Summary · SB 1804

Legislative bill overview

SB 1804 prohibits Missouri's professional licensing boards from granting exemptions, waivers, or rule modifications to individuals or businesses that are developing artificial intelligence systems for prescribing, dispensing, administering, or distributing medications and controlled substances. The bill essentially bars regulatory flexibility for AI-driven pharmaceutical distribution activities.

Why is this important

As AI increasingly enters healthcare, this bill takes a restrictive stance on how AI can participate in medication management. It could significantly impact telemedicine expansion, pharmacy automation, and AI-assisted prescription systems by preventing regulatory boards from adapting their rules to accommodate new technologies, even if those technologies might improve efficiency or access to care.

Potential points of contention

  • Innovation vs. Safety: The bill may stifle beneficial healthcare AI development by refusing any regulatory accommodation, versus supporters' concern that AI prescribing requires strict oversight without exceptions
  • Scope Definition: Unclear whether "developing...artificial intelligence for such prescription activities" captures only direct AI prescribing systems or broader health IT tools, creating ambiguity about what's actually prohibited
  • Market Impact: Could disadvantage Missouri-based AI healthcare companies and telemedicine platforms compared to states with more flexible regulatory frameworks, potentially driving innovation and jobs elsewhere
  • Patient Access: May prevent regulatory boards from approving AI systems that could expand medication access in rural or underserved areas where human providers are scarce

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.